RNXT RenovoRx, Inc.

$2.34 -9.30%

Updated 16 d ago

Healthcare · Pharmaceutical Preparations

RenovoRx, Inc. (RNXT) is a healthcare company in the Pharmaceutical Preparations industry, with a market capitalization of $106 million. Shares last traded at $2.34, 15.2% below their 52-week high. Over the past year the stock is up 89.5%. Net profit margin is -621.7%, below the peer median of -8.9%. Revenue grew 2511.6% year over year.

Market Cap

$106M

Shares Out

45.1M

EPS (TTM)

$-0.64

P/E Ratio

—

P/S Ratio

53.44

P/B Ratio

11.76

Dividend / Share

—

Dividend Yield

—

52-Week High

$2.76

52-Week Low

$0.70

Volume

76,560

Avg Vol (3m)

14,666.984

Performance

+59.18%

+119.72%

+139.98%

+183.98%

YTD

+180.41%

+89.47%

Chart

Full chart →

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)

76.25

SMA (50)

$1.15

SMA (200)

$0.98

Price vs SMA50

+102.67%

Price vs SMA200

+137.73%

ATR (14)

$0.22

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue

$2M

Net Income

$-12M

Gross Margin

84.4%

Operating Margin

-685.2%

Net Margin

-621.7%

Return on Equity

-136.8%

Return on Assets

-107.1%

Current Ratio

5.74

Debt / Equity

0.28

Revenue Growth (YoY)

+2511.6%

Latest reported annual period ending 2026-06-30 · SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Recent earnings

Period	EPS (diluted)	Reported
Q2 2026	$-0.15	2026-08-13
Q1 2026	$-0.09	2026-05-14
FY 2025	$-0.32	2026-03-30
Q3 2025	$-0.24	2025-11-13
Q2 2026	$-0.16	2026-08-13
Q1 2026	$-0.08	2026-05-14

Full earnings history →

Pharmaceutical Preparations peers

RNXT vs 14 industry peers (Pharmaceutical Preparations), by market cap. Updated 16 d ago

P/S vs peers

53.44 / 11.11 med

+381% premium

Net margin vs peers

-621.7% / -8.9% med

below median

1–14 of 14


LLY	Lilly (Eli)	$1.09T	40.86	13.70	33.5%	-0.02%
JNJ	Johnson & Johnson	$670.6B	31.88	6.85	21.5%	+1.04%
ONC	Beone Medicines Ltd.	$535.9B	817.25	87.43	10.7%	+0.23%
ABBV	AbbVie	$459.8B	72.87	7.14	9.8%	-0.57%
MRK	Merck	$375.8B	118.44	5.65	4.8%	+0.44%
ABT	Abbott Laboratories	$189.5B	30.20	4.20	13.9%	-1.50%
PFE	Pfizer	$164.2B	37.91	2.58	6.8%	-0.76%
VRTX	Vertex Pharmaceuticals	$141.5B	32.11	11.24	35.0%	+0.24%
BMY	Bristol Myers Squibb	$139.1B	14.98	2.83	18.9%	+0.62%
REGN	Regeneron Pharmaceuticals	$87.2B	20.15	5.61	27.9%	-1.02%
TEVA	Teva Pharmaceutical Industries Ltd	$42.6B	60.41	2.46	4.1%	-2.32%
ALNY	Alnylam Pharmaceuticals	$35.4B	43.77	9.52	21.8%	-1.10%
ZTS	Zoetis	$31.5B	12.05	3.31	27.5%	+0.16%
RPRX	Royalty Pharma Plc	$28.2B	34.56	11.11	32.1%	+1.24%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.